Concepedia

Author

Christian Manegold

Heidelberg University

Also Known As

C Manegold, Christian MANEGOLD, Christian Manegold, Manegold, Christian

157

Publications

21.7K

Citations

46

H-Index

58

Concepts

All Affiliations

Heidelberg UniversityUniversity Hospital HeidelbergUniversity Medical Centre MannheimLungenClinic GrosshansdorfInstitut Català d'Oncologia
CM

About

Christian Manegold is an author at Heidelberg University specializing in medicine, radiation oncology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

22

34

2.6K

2

Health Sciences

6

6

627

3

Engineering

3

3

60

4

Cell Biology

1

1

73

5

Geriatrics

1

1

10

Christian Manegold

×

61

Publications

20K

Citations

39

H-Index

YearCitations

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

Giorgio V. Scagliotti, Purvish Parikh, Joachim von Pawel,

Journal of Clinical Oncology

2008

3.2K

Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma

Nicholas J. Vogelzang, James J. Rusthoven, James T. Symanowski,

Journal of Clinical Oncology

2003

3K

Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy

Nasser H. Hanna, Frances A. Shepherd, Frank V. Fossella,

Journal of Clinical Oncology

2004

2.4K

Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1

Giuseppe Giaccone, Roy S. Herbst, Christian Manegold,

Journal of Clinical Oncology

2004

1.7K

Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2

Roy S. Herbst, Giuseppe Giaccone, Joan H. Schiller,

Journal of Clinical Oncology

2004

1.7K

Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

Martin Reck, Joachim von Pawel, Petr Zatloukal,

Journal of Clinical Oncology

2009

1.5K

Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada

Jan P. van Meerbeeck, Rabab Gaafar, Christian Manegold,

Journal of Clinical Oncology

2005

621

Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials

Daphne W. Bell, Thomas J. Lynch, Sara M. Haserlat,

Journal of Clinical Oncology

2005

607

Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid: Subgroup Analysis from a Randomized Phase 3 Study

Giorgio V. Scagliotti, Vera Hirsh, Salvatore Siena,

Journal of Thoracic Oncology

2012

339

Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung Adenocarcinomas

Miguel Tarón, Yukito Ichinose, Rafael Rosell,

Clinical Cancer Research

2005

336

Page 1